Search

Displaying results 4521 - 4530 of 7497 in total
  1. Drug

    ChAd-triCoV/Mac

    go.drugbank.com/drugs/DB24997
    Investigational

    ChAd-triCoV/Mac is under investigation in clinical trial NCT06381739 (A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol).

  2. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis.

  3. Drug

    Equilenin

    go.drugbank.com/drugs/DB03515
    Experimental

    Equilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.

  4. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity

  5. Drug

    Bromazepam

    go.drugbank.com/drugs/DB01558
    ApprovedIllicit

    It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.

    Products: BROMAZEPAM N&P
  6. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.

  7. Drug

    SCB-2019

    go.drugbank.com/drugs/DB15805
    Investigational

    The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

  8. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. … Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease

  9. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  10. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)